• Publications
  • Influence
Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results
TLDR
The combined clinimetric results of this study support the validity of the MDS‐UPDRS for rating PD. Expand
Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients.
TLDR
Dopamine agonist treatment in PD is associated with 2- to 3.5-fold increased odds of having an ICD, which represents a drug class relationship across ICDs. Expand
Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan
TLDR
The MDS‐UPDRS retains the UPDRS structure of four parts with a total summed score, but the parts have been modified to provide a section that integrates nonmotor elements of PD: I, Nonmotor Experiences of Daily Living; II, Motor Exper experiences of daily Living; III, Motor Examination; and IV, Motor Complications. Expand
MDS clinical diagnostic criteria for Parkinson's disease
TLDR
The Movement Disorder Society PD Criteria retain motor parkinsonism as the core feature of the disease, defined as bradykinesia plus rest tremor or rigidity, and two levels of certainty are delineated: clinically established PD and probable PD. Expand
Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease.
TLDR
It is suggested that the firing of STN neurones can be synchronized by 15-30 Hz cortical beta oscillatory activity, particularly when dopamine deficiency results in a higher background firing rate of STn neurones, and that this synchronization contributes to parkinsonian pathophysiology. Expand
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.
TLDR
Early Parkinson's disease can be managed successfully for up to five years with a reduced risk of dyskinesia by initiating treatment with ropinirole alone and supplementing it with levodopa if necessary. Expand
Levodopa and the progression of Parkinson's disease.
TLDR
The clinical data suggest that levodopa either slows the progression of Parkinson's disease or has a prolonged effect on the symptoms of the disease, and the neuroimaging data suggest either thatlevodopa accelerates the loss of nigrostriatal dopamine nerve terminals or that its pharmacologic effects modify the dopamine transporter. Expand
Criteria for the diagnosis of corticobasal degeneration
TLDR
Clinical CBD phenotypes and features were combined to create 2 sets of criteria: more specific clinical research criteria for probable CBD and broader criteria for possible CBD that are more inclusive but have a higher chance to detect other tau-based pathologies. Expand
Phenomenology and classification of dystonia: A consensus update
TLDR
An international panel consisting of investigators with years of experience in this field that reviewed the definition and classification of dystonia provides a new general definition and proposes a new classification and encourages clinicians and researchers to use these innovative definitions and test them in the clinical setting on a variety of patients with Dystonia. Expand
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study
TLDR
Mutations in LRRK2 are a clinically relevant cause of PD that merit testing in patients with hereditary PD and in subgroups of patients with PD, but this knowledge should be applied with caution in the diagnosis and counselling of patients. Expand
...
1
2
3
4
5
...